{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Cell lines with known inactivating BRCA1 or BRCA2 mutations, BRCAI promoter', 'methylation or other DNA repair defects e.g., Meiotic Recombination 11 (MRE11; MRE11A),', 'were also included. The panel was also profiled for relative protein and messenger ribonucleic', 'acid gene expression levels of key DNA damage response (DDR) and HRR associated genes', 'such as BRCA1, BRCA2, ATM, ATR, mediator of DNA damage checkpoint protein 1 and', 'MRE11A.', 'A cell line was classified as HRD when either relative gene or protein expression for 2 or', 'more HRR target genes was less the half (50%, 0.5) relative to the mean expression. Cell lines', 'with published literature confirming deleterious, homozygous loss-of-function BRCAI or', 'BRCA2 mutations were also classed as HRD [79-82].', '11.0', 'Tissue Type', 'Number cell lines', '10.0', 'Colorectal', '14', 'Breast', '25', 'Ovarian', '14', '9.0', 'Lung', '15', 'Pancreatic', '12', '8.0', 'Head&Neck SCC', '15', '7,0', '6.0', '5.0', '4.0', '3.0', '2.0', '1.0', '0,0', 'Cell Line (number)', 'Figure 8: Graphical plot of olaparib activity (IC50) across the KU95 cell line panel.', 'While a broad range, continuum of growth inhibitory (IC50) activity for olaparib was observed', 'across the cell line panel (ranging from 0.018 M through to >10 M), associations with', 'enhanced olaparib sensitivity (IC50 <1 M) were observed in cell lines with known BRCAI or', 'BRCA2 mutations or low expression of HRR genes/proteins (Figure 9. These data are', 'consistent with the proposed mechanism of action of PARP inhibitors, where deficiencies in', 'HR lead to an inability to repair DNA DSBs resulting from PARP inhibitor treatment. While', 'there is a clear enrichment for HRD within the most sensitive cell lines (24/30), there are still', 'responsive cell lines for which a molecular basis has not yet been ascribed.', '18(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '1.200', 'BRCA', 'Low BRCA', 'Non-BRCA', 'Unknown', 'Mutant', 'Expression', 'low HRR expression', 'defect', '1.000', '0.800', '0.600', '0.400', '0.200', '0.000', 'Figure 9: Graphical plot of olaparib sensitive cell lines (IC50 <uM) arranged by known', 'BRCA1/2 mutation status or low expression of HRR genes.', 'Plot of highly olaparib sensitive cell lines (IC50<1 M) clustered by the presence known deleterious', 'BRCA1/2 mutations (BRCA mutant), low BRCA1/2 expression (low BRCA expression), low', 'expression of 1or more HR genes in the absence of BRCA1/2 mutation/low expression (non-BRCA,', 'low HRR expression) or those without any of these defects (unknown defect).', 'Similarly, in vivo orthotopic BRCA knockout models testing olaparib showed marked anti-', 'tumor effects. In both a BRCA1-/- orthotopic mouse mammary tumor model and a BRCA2- /-', 'orthotopic mouse model, dosing with 50 mg/kg olaparib once daily (od) for 28-days showed', 'significant anti-tumor efficacy for single agent olaparib [71, 72].', 'An analysis of the correlation of olaparib response with several standard-of-care', 'chemotherapies in a panel of breast cancer cell lines demonstrated a strong correlation with', 'both carboplatin (0.84, p=0.0006) and camptothecin (0.8, p=0.0018). This is consistent with', 'what is known about the types of DNA damage they induce (intra-strand and inter-strand', 'cross-links for platinum and trapped topoisomerases-DNA adducts for camptothecins, both of', 'which result in DNA DSB formation in replicating cells) and the DDR pathways that deal', 'with them (primarily HRR in cells undergoing DNA replication). The same does not hold for', 'a mechanistically unrelated chemotherapy, such as paclitaxel (-0.11) whose mechanism of', 'action is unrelated to the induction of DNA damage.', 'An analysis of olaparib and platinum response across several tumor cell lines indications', 'where platinum treatment is standard-of-care and included ovarian, non-small cell lung cancer', '(NSCLC) and head and neck squamous cell carcinoma cell lines. Consistent with the breast', 'cancer cell line data, the strong correlation between platinum response and olaparib response', 'was observed both in vitro (Figure 10) and in vivo.', '19(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}